Also known as: SOTIO
SOTIO Biotech is a clinical-stage immuno-oncology company owned by PPF Group and focused on developing novel antibody-drug conjugates and immune-modulating therapies. Its pipeline includes SOT102, SOT201, and other oncology programs built on next-generation antibody engineering.
LigaChem Biosciences is expanding R&D investment in its ADC pipeline despite widening losses, with major clinical milestones expected this year. Concurrently, Lonza has enhanced its advanced synthesis capabilities for ADC development, including dual-payload technology and expanded Netherlands facility infrastructure.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
